Mechanism of Action
Smad2/3-Mediated Muscle Suppression
Myostatin binds ActRIIB (primary receptor) with high affinity. ActRIIB transphosphorylates ALK4 or ALK5, which phosphorylates Smad2/3. Smad2/3-Smad4 complex translocates to the nucleus, activating MSTN, Atrogin-1, MuRF1 (muscle-specific ubiquitin ligases promoting protein degradation) while suppressing MyoD and IGF-1 signaling (which drive hypertrophy). Net effect: reduced protein synthesis, increased protein degradation, impaired satellite cell activation.
Regulation and Activation
Myostatin is secreted as a latent complex with its N-terminal prodomain (LTBP). Activation requires BMP-1/tolloid metalloprotease cleavage to release active myostatin, allowing ActRIIB binding. Follistatin, FSTL3, and decorin bind mature myostatin to prevent receptor engagement. The propeptide itself can serve as a dominant negative -- synthetic propeptides and modified propeptides are being developed as therapeutics.
Research Summary
Duchenne/Becker MD and SMA
Phase 2/3Apitegromab (SRK-015, myostatin propeptide) Phase 2 (TOPAZ) in SMA: significant improvements in motor function scores in ambulatory SMA patients on background SMN therapy. Phase 3 DRAGON trial ongoing. Landogrozumab (anti-myostatin antibody) in DMD: Phase 3 RESILIENCE trial ongoing. Combined myostatin inhibition + SMN restoration is a promising two-pronged strategy for SMA.
Sarcopenia and Cancer Cachexia
Phase 2Bimagrumab (anti-ActRIIB antibody, blocks myostatin+activin) Phase 2 in type 2 diabetes and obesity: 21% lean mass increase, 20% fat mass reduction over 48 weeks without diet or exercise change. Anti-myostatin specific antibodies in sarcopenia trials show 2-5% lean mass gains in elderly subjects. Cancer cachexia trials of multiple agents ongoing.
Myostatin-Null Phenotype
EstablishedGDF-8 knockout mice: 2-3x normal muscle mass, normal metabolic health, reduced fat mass. Double-muscled cattle: extreme muscle hypertrophy, reduced fat, calving difficulties due to size. Human myostatin-null child (Schuelke, 2004): exceptional muscle development identified at birth; continued extraordinary strength into childhood with no adverse effects reported. These natural experiments validate myostatin inhibition for human muscle enhancement.
Calculate your Myostatin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Myostatin inhibition research (antibody) | 10-30 mg/kg IV/SC in rodent models | 1-2x/week | Subcutaneous or intravenous |
| Myostatin measurement (research) | Serum ELISA; normal: 2-5 ng/mL; elevated in sarcopenia/aging | Single measurement | Blood draw |
Research uses recombinant myostatin to establish inhibition dose-response; clinical trials target inhibition not agonism. WADA prohibits myostatin inhibitors in sport.
Interactions
Safety Profile
Myostatin-null mammals are healthy with no metabolic dysfunction beyond reproductive complications in cattle (large calves cause difficult deliveries). Human myostatin-null child: no adverse effects. Anti-myostatin antibody trials: generally well tolerated; muscle cramping and pain in some subjects; injection site reactions. Bimagrumab (ActRIIB blocker): telangiectasias, falls, diarrhea, erythema in >10% of subjects. Concern about cardiac hypertrophy with sustained ActRIIB blockade in preclinical models; human cardiac monitoring included in most trials. WADA prohibited for sport due to perceived doping benefit.
References
- [1]McPherron AC, et al. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387(6628):83-90.
- [2]Schuelke M, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350(26):2682-2688.
- [3]Hayhurst M, et al. Apitegromab for spinal muscular atrophy (TOPAZ). N Engl J Med. 2023;389(6):513-524.